Pharmacogenomic biomarkers are increasingly listed on medication labels and authoritative guidelines but pharmacogenomic-guided prescribing is not yet common. Our objective was to assess the potential for incorporating knowledge of patients’ genomic characteristics into prescribing practices.
We performed a retrospective analysis of claims data for 2,096,971 beneficiaries with pharmacy coverage from a national, commercial health insurance plan between January 2017 and December 2019. Children between 0 and 17 years comprised 21% of the cohort. Adults were age 18 to 64. Medications with actionable pharmacogenomic biomarkers (MAPBs) were identified using public information from the US Food and Drug Administration (FDA), Clinical Pharmacogenomics Implementation Consortium (CPIC), and PharmGKB.
MAPBs were dispensed to 63% of the adults and 29% of the children in the cohort. Most frequently dispensed were ibuprofen, ondansetron, codeine, and oxycodone. Most common were medications with CYP2D6, G6PD, or CYPC19 pharmacogenomic biomarkers. Ten percent of the cohort were codispensed more than one MAPB for at least 30 days.
The number of people who might benefit from pharmacogenomic-guided prescribing is substantial. Future work should address obstacles to integrating genomic data into prescriber workflows, complex factors contributing to the magnitude of benefit, and the clinical availability of reliable on-demand or pre-emptive pharmacogenomic testing.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Raw data for this study were pharmacy claims and membership and enrollment information from a private insurer. The Data Use Agreement does not allow the investigators to share these beneficiary level data. The supplementary materials contain counts derived from the raw data files. In particular, Supplementary Table 2 has counts of the number of enrollees who were dispensed each MAPB by age group and for the whole cohort.
Abbasi, J. Getting pharmacogenomics into the clinic. JAMA 316, 1533–1535 (2016).
Relling, M. V., Klein, T. E. & Gammal, R. S. et al. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin. Pharmacol. Ther. 107, 171–175 (2020).
Whirl-Carrillo, M., McDonagh, E. M. & Hebert, J. M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414–417 (2012).
Samwald, M., Xu, H. & Blagec, K. et al. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One 11, e0164972 (2016).
Chanfreau-Coffinier, C., Hull, L. E. & Lynch, J. A. et al. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among US Veterans Health Administration pharmacy users. JAMA Netw. Open 2, e195345 (2019).
Shehab, N., Lovegrove, M. C. & Geller, A. I. et al. US emergency department visits for outpatient adverse drug events, 2013-4. JAMA. 316, 2115–2125 (2016).
Auton, A., Brooks, L. D. & Durbin, R. M. et al. A global reference for human genetic variation. Nature. 526, 68–74 (2015).
Smith, D. M., Peshkin, B. N., Springfield, T. B. et al. Pharmacogenetics in practice: estimating the clinical actionability of pharmacogenetic testing in perioperative and ambulatory settings. Clin. Transl. Sci. 13, 618–627 (2020).
Relling, M. V. & Evans, W. E. Pharmacogenomics in the clinic. Nature. 526, 343–350 (2015).
Kho, A. N., Rasmussen, L. V. & Connolly, J. J. et al. Practical challenges in integrating genomic data into the electronic health record. Genet. Med. 15, 772–778 (2013).
Mandl, K. D. & Kohane, I. S. No small change for the health information economy. N. Engl. J. Med. 360, 1278–1281 (2009).
Manzi, S. F., Fusaro, V. A. & Chadwick, L. et al. Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration—experience from a pediatric tertiary care facility. J. Am. Med. Inform. Assoc. 24, 74–80 (2017).
Mathias, P. C., Hendrix, N. & Wang, W. J. et al. Characterizing pharmacogenomic-guided medication use with a clinical data repository. Clin. Pharmacol. Ther. 102, 340–348 (2017).
Warner, J. L., Jain, S. K. & Levy, M. A. Integrating cancer genomic data into electronic health records. Genome Med. 8, 113 (2016).
Vassy, J. L., Stone, A. & Callaghan, J. T. et al. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. Genet. Med. 21, 382–390 (2019).
Gammal, R. S., Caudle, K. E., Klein, T. E. & Relling, M. V. Considerations for pharmacogenomic testing in a health system. Genet. Med. 21, 1886–1887 (2019).
Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093–1098 (2018).
This study was supported by a postdoctoral fellowship from Aetna (D.L.), funding from the Boston Children’s Hospital PrecisionLink Initiative, and by cooperative agreement U01TR002623 from the National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH) and R01GM104303 from The National Institute of General Medical Sciences (NIGMS), NIH. None of the funding organizations influenced the design of the study, or the collection, analysis, or interpretation of the data.
Boston Children’s Hospital Institutional Review Board approved waiving consent for this study. Risks were determined to be minimal with no potential for direct benefit. Aetna gave approval for the manuscript submission, confirming that no beneficiaries were identifiable.
S.F.M. is a Scientific Advisory Board member at Global Gene, Inc. Quest Diagnostics sponsors research for and contributes philanthropy for K.D.M.’s research program at Boston Children’s Hospital. The other authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, D., Olson, K.L., Manzi, S.F. et al. Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics. Genet Med (2021). https://doi.org/10.1038/s41436-020-01044-2